Mantle cell lymphoma other imaging findings: Difference between revisions
No edit summary |
No edit summary |
||
| (11 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ Mantle cell lymphoma }} | {{Mantle cell lymphoma }} | ||
{{CMG}} | {{CMG}}; {{AE}} {{AS}} {{Akram}} | ||
==Overview== | ==Overview== | ||
==Other Imaging | [[PET scan]] ([[positron emission tomography]]) integrated with [[Computed tomography|CT scan]] may be helpful in the [[Cancer staging|staging]] and treatment response assessment of mantle cell lymphoma. | ||
==Other Imaging Studies== | |||
There seems to no concrete consensus about the usefulness of [[PET scan|PET/CT scan]] in [[lymphomas]]. However, in some studies it has been shown that it may be helpful in the [[Cancer staging|staging]] and treatment response assessment of [[mantle cell lymphoma]], which is considered a [[fluorodeoxyglucose]] ([[FDG]])-avid [[tumor]] and shows activity on the [[PET scan]].<ref>{{Cite journal | |||
== | | author = [[Saar Gill]], [[Max Wolf]], [[H. Miles Prince]], [[Henry Januszewicz]], [[David Ritchie]], [[Rodney J. Hicks]] & [[John F. Seymour]] | ||
| title = [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma | |||
=== | | journal = [[Clinical lymphoma & myeloma]] | ||
| volume = 8 | |||
| issue = 3 | |||
| pages = 159–165 | |||
| year = 2008 | |||
| month = June | |||
| doi = 10.3816/CLM.2008.n.019 | |||
| pmid = 18650179 | |||
}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{Hematology}} | {{Hematology}} | ||
[[Category:Blood disorders]] | [[Category:Blood disorders]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
| Line 25: | Line 32: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hematology]] | |||
[[Category:Immunology]] | |||
Latest revision as of 20:19, 7 January 2019
|
Mantle cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mantle cell lymphoma other imaging findings On the Web |
|
American Roentgen Ray Society Images of Mantle cell lymphoma other imaging findings |
|
Risk calculators and risk factors for Mantle cell lymphoma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2] Ali Akram, M.B.B.S.[3]
Overview
PET scan (positron emission tomography) integrated with CT scan may be helpful in the staging and treatment response assessment of mantle cell lymphoma.
Other Imaging Studies
There seems to no concrete consensus about the usefulness of PET/CT scan in lymphomas. However, in some studies it has been shown that it may be helpful in the staging and treatment response assessment of mantle cell lymphoma, which is considered a fluorodeoxyglucose (FDG)-avid tumor and shows activity on the PET scan.[1]
References
- ↑ Saar Gill, Max Wolf, H. Miles Prince, Henry Januszewicz, David Ritchie, Rodney J. Hicks & John F. Seymour (2008). "[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma". Clinical lymphoma & myeloma. 8 (3): 159–165. doi:10.3816/CLM.2008.n.019. PMID 18650179. Unknown parameter
|month=ignored (help)